Ruben Mesa
0000-0001-5880-7972
8 papers found
Refreshing results…
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)‐I study
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera
Fedratinib in myelofibrosis
Missing publications? Search for publications with a matching author name.